期刊
MEDCHEMCOMM
卷 5, 期 9, 页码 1371-1380出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c4md00206g
关键词
-
资金
- Quaid-I-Azam University Islamabad Research Fund
- HEC
- Jurgen Manchot Foundation, Dusseldorf, Germany
- COMSTECH-TWAS
- German-Pakistani Research Collaboration Programme
Two new series of oxothiazolidine benzoate and acetate derivatives were synthesized and evaluated as aldehyde reductase (ALR1) and aldose reductase (ALR2) inhibitors. Methyl 2-[2-benzamido-3-(benzo[d] thiazol-2-yl)-4-oxothiazolidin-5-ylidene]acetates (2a-k) and ethyl 4-[2-benzamido-5-(2-methoxy-2-oxyethylidene)- 4-oxothiazolidin-3-yl]benzoates (4a-j) were obtained in good to excellent yield by the heterocyclization of 1-aroyl-3-(2-benzothiazolyl) thioureas (1a-j) and ethyl 4-(3-aroylthioureido) benzoates (3a-j), respectively, with dimethyl acetylenedicarboxylate (DMAD) in dry methanol. Among the tested compounds, 2d, 2g, 2h, 2i, 2j, 4b, 4f and 4h showed a potent inhibitory activity on ALR1, whereas 2a, 2g, 2h, 4d, 4f, 4h and 4j exhibited potent inhibition on ALR2. Docking analysis suggested the likely binding modes of the inhibitors within the active site of ALR2. The new aldose reductase inhibitors are believed to represent useful lead structures for the generation of candidate compounds to target a number of pathological conditions, most notably long-term diabetic complications. FTIR, H-1 NMR, C-13 NMR, GC-MS and elemental analyses confirmed the assigned structures to the synthesized compounds. Further, the structure and geometry of compound ethyl 4-((2Z, 5Z)-22,4-di-(2,4-dichlorobenzoylimino)-5-( 2-methoxy-2-oxoethylidene)-4-oxothiazolidin-3-yl)benzoate (4c) was unequivocally confirmed by single crystal X-ray diffraction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据